Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Nov
10
Today In Oncology
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
Two Forever Chemicals Associated Higher Risk of ER-Negative Breast Cancer
Methylphenidate May Reduce Cancer-Related Fatigue in Patients With Hematologic Malignancies
Extended Follow-up of Nivolumab Ipilimumab for Localized dMMR MSI-H Gastric GEJ Cancer
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo